Physiomics. Rational Therapeutics

Dr Paul Harper, Chairman

Dr Paul Harper has over 30 years' experience in the life sciences industry covering both drug development and medical devices. He is Chairman of Physiomics plc, Sareum plc, Angel Biotechnology Holdings plc and Director of Reneuron Holdings plc, all AIM quoted companies.  In addition, he is chairman of FDAS Ltd, and Monica Healthcare Ltd. Paul has served as Chief Executive of Cambridge Antibody Technology Limited, and founded Provensis Limited. He has also served as Corporate Development Director of Unipath Limited, then the medical diagnostics business of Unilever PLC, and as Director of Research and Development for Johnson & Johnson Limited. Formerly head of Antimicrobial Chemotherapy for Glaxo PLC, Paul has a PhD in Molecular Virology and is the author of over 50 publications.

Dr Mark Chadwick, Chief Executive Officer

Mark joined Physiomics from EnviroGene in December 2010.  Previously he was VP of Business Development at Excelsyn, a chemistry services provider, where he grew turnover to £14m and EBITDA to £1m. Excelsyn was subsequently acquired by AMRI for $19m. Prior to that he led the Development Services Business Unit at Excelsyn, growing the customer base from scratch to over 80 in 3 years.  Before joining Excelsyn, Mark spent 10 years in Cambridge from startup company (Cambridge Genetics Limited) through two mergers to become Director of Commercial Operations at BioFocus, a £15m turnover, profitable drug discovery services provider. BioFocus was subsequently acquired by the Belgian biotechnology company Galapagos for $40m.

Mark is a former Fellow of Corpus Christi College Cambridge. He holds an MBA with distinction in Entrepreneurship from Imperial College London, a PhD in Molecular Biology from The University of Newcastle and a 1st Class (Hons) degree in Genetics from the University of Nottingham.

Dr Christophe Chassagnole, Chief Operating Officer

Dr Christophe Chassagnole has been involved in systems biology and bio-computing projects since the mid-nineties, with experience in both academic and industrial environments. His Doctorate was achieved at the Victor Segalen-Bordeaux II University, and then he held a post doctorate position with IBVT at Stuttgart University. Before Joining Physiomics Dr Chassagnole worked in France as a senior researcher for CRITT Bio-Industries (Toulouse) for 3 years. He joined Physiomics in May 2004 as project leader to develop the model portfolio of the company. He was appointed Chief Operating Officer of Physiomics in May 2007.

Mr Roger Jones, Financial Controller and Company Secretary

Mr. Jones has for 30 years been a Fellow of the Association of Chartered Certified Accountants and has held a number of senior financial positions and key roles in biotechnology and pharmaceutical companies including Cambridge Antibody Technology, Onyvax, Archimedes Pharma, Angel Biotechnology and Provensis.